Antibiotic Resistance Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Antibiotic Resistance Market, Disease

7.1.  Antibiotic Resistance Market, Disease, 2021-2028

7.1.1.    Complicated Urinary Tract Infection (cUTI)

7.1.1.1.        Market Revenue and Forecast (2016-2028)

7.1.2.    Complicated Intra-Abdominal Infections (cIAI)

7.1.2.1.        Market Revenue and Forecast (2016-2028)

7.1.3.    Blood Stream Infections (BSI)

7.1.3.1.        Market Revenue and Forecast (2016-2028)

7.1.4.    Clostridium difficile infections (CDI)

7.1.4.1.        Market Revenue and Forecast (2016-2028)

7.1.5.    Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

7.1.5.1.        Market Revenue and Forecast (2016-2028)

7.1.6.    Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)

7.1.6.1.        Market Revenue and Forecast (2016-2028)

7.1.7.    Community Acquired Bacterial Pneumonia (CABP)

7.1.7.1.        Market Revenue and Forecast (2016-2028)

Chapter 8.  Global Antibiotic Resistance Market, Pathogen

8.1.  Antibiotic Resistance Market, Pathogen, 2021-2028

8.1.1.    Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)

8.1.1.1.        Market Revenue and Forecast (2016-2028)

8.1.2.    Pseudomonas aeruginosa (Carbapenem-Resistant)

8.1.2.1.        Market Revenue and Forecast (2016-2028)

8.1.3.    Staphylococcus Aureus (Methicillin-Resistant)

8.1.3.1.        Market Revenue and Forecast (2016-2028)

8.1.4.    E. coli/K. pneumoniae (Carbapenem-Resistant)

8.1.4.1.        Market Revenue and Forecast (2016-2028)

8.1.5.    Streptococcus pneumoniae (Penicillin-Non-Susceptible)

8.1.5.1.        Market Revenue and Forecast (2016-2028)

8.1.6.    Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)

8.1.6.1.        Market Revenue and Forecast (2016-2028)

8.1.7.    Enterococcus faecium (Vancomycin-Resistant)

8.1.7.1.        Market Revenue and Forecast (2016-2028)

8.1.8.    Haemophilus Influenzae (Ampicillin-Resistant)

8.1.8.1.        Market Revenue and Forecast (2016-2028)

Chapter 9.  Global Antibiotic Resistance Market, By Drug Class

9.1.  Antibiotic Resistance Market, By Drug Class, 2021-2028

9.1.1.    Oxazolidinones

9.1.1.1.        Market Revenue and Forecast (2016-2028)

9.1.2.    Lipoglycopeptides

9.1.2.1.        Market Revenue and Forecast (2016-2028)

9.1.3.    Tetracyclines

9.1.3.1.        Market Revenue and Forecast (2016-2028)

9.1.4.    Cephalosporins

9.1.4.1.        Market Revenue and Forecast (2016-2028)

9.1.5.    Combination therapies

9.1.5.1.        Market Revenue and Forecast (2016-2028)

Chapter 10.      Global Antibiotic Resistance Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, Disease (2016-2028)

10.1.2.  Market Revenue and Forecast, Pathogen (2016-2028)

10.1.3.  Market Revenue and Forecast, By Drug Class (2016-2028)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, Disease (2016-2028)

10.1.4.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.1.4.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, Disease (2016-2028)

10.1.5.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.1.5.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, Disease (2016-2028)

10.2.2.  Market Revenue and Forecast, Pathogen (2016-2028)

10.2.3.  Market Revenue and Forecast, By Drug Class (2016-2028)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, Disease (2016-2028)

10.2.4.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.2.4.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, Disease (2016-2028)

10.2.5.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.2.5.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, Disease (2016-2028)

10.2.6.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.2.6.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, Disease (2016-2028)

10.2.7.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.2.7.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, Disease (2016-2028)

10.3.2.  Market Revenue and Forecast, Pathogen (2016-2028)

10.3.3.  Market Revenue and Forecast, By Drug Class (2016-2028)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, Disease (2016-2028)

10.3.4.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.3.4.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, Disease (2016-2028)

10.3.5.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.3.5.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, Disease (2016-2028)

10.3.6.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.3.6.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, Disease (2016-2028)

10.3.7.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.3.7.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, Disease (2016-2028)

10.4.2.  Market Revenue and Forecast, Pathogen (2016-2028)

10.4.3.  Market Revenue and Forecast, By Drug Class (2016-2028)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, Disease (2016-2028)

10.4.4.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.4.4.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, Disease (2016-2028)

10.4.5.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.4.5.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, Disease (2016-2028)

10.4.6.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.4.6.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, Disease (2016-2028)

10.4.7.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.4.7.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, Disease (2016-2028)

10.5.2.  Market Revenue and Forecast, Pathogen (2016-2028)

10.5.3.  Market Revenue and Forecast, By Drug Class (2016-2028)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, Disease (2016-2028)

10.5.4.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.5.4.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, Disease (2016-2028)

10.5.5.2.      Market Revenue and Forecast, Pathogen (2016-2028)

10.5.5.3.      Market Revenue and Forecast, By Drug Class (2016-2028)

Chapter 11.  Company Profiles

11.1.              Pfizer

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Merck

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Allergan

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Melinta

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

Glossary of Terms